You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test will be included in the World Health Organizations list of prequalified in vitro diagnostics and UN agencies will be able to procure it.
According to New Scientist, the transatlantic slave trade may have introduced diseases like yaws and hepatitis B to the Americas.
The test is the second infectious disease assay from Bioneer to be CE marked, and the South Korean company has a third test in the pipeline.
The assay is based on the company's AmpiProbe technology, which uses fluorescent reporter-labeled primers and quencher-labeled primers to amplify DNA.
In PLOS this week: reference bias effects in ancient genomics, tsetse fly genetic diversity, and more.
In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
The test measures hepatitis B viral DNA and is intended to be used to assess prognosis and response to antiviral therapies.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.
In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.